Litcius/Paper detail

LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

Nicolas Girard, Santiago Ponce Aix, S. Cedrés, Thierry Berghmans, Sjaak Burgers, A.C. Toffart, Sanjay Popat, Annelies Janssens, R. Gervais, M. Hochstenbag, Mario Silva, Irene A. Burger, Helmut Prosch, Rolf A. Stahel, A-S. Govaerts, Alessia Pochesci, Anouk Neven, Solange Peters

2021Annals of Oncology13 citationsDOI

Topics & Concepts

MedicineNivolumabThymic carcinomaThymomaInternal medicineOncologyPhases of clinical researchClinical trialSurgeryCancerImmunotherapyMyasthenia Gravis and ThymomaCancer Treatment and Pharmacology
LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial | Litcius